ProCE Banner Activity

Managing the Toxicities of TROP-2 Antibody‒Drug Conjugates in Lung Cancer


Watch this video for an expert-guided tour through an infographic capturing best practices for identifying and managing key toxicities associated with TROP2 ADCs in lung cancer care.

Released: June 08, 2023



Rebecca S. Heist

Rebecca S. Heist, MD, MPH

Associate Professor of Medicine
Harvard Medical School
Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts

Provided by

Provided by Clinical Care Options LLC

ProCE Banner


This activity is supported by an educational grant from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc.


Daiichi Sankyo, Inc.

Gilead Sciences, Inc.


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Rebecca S. Heist, MD, MPH

Associate Professor of Medicine
Harvard Medical School
Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts

Rebecca S. Heist, MD, MPH: consultant/advisor/speaker: AbbVie, AstraZeneca, Claim Therapeutics, Daiichi Sankyo, EMD Serono, Lilly, Novartis, Regeneron, Sanofi; researcher (paid to institution): AbbVie, Agios, Corvus, Daichii Sankyo, Erasca, Lilly, Mirati, Novartis, Turning Point.

The planners and content peer reviewers from Clinical Care Options, LLC have no relevant financial relationships to disclose.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.